The Future of Rosacea Treatment

  • Frank C. PowellEmail author
  • Maeve A. McAleer


The future of rosacea treatment will depend on developing an understanding of the aetiology and pathogenesis of the various components that result in this common cutaneous disorder. Appropriate therapy can then be directed at causative factors with the objective of preventing the development of the more florid manifestations of the disease. Until that knowledge is available treatment will be directed at the different clinical features that present in rosacea patients.


Azelaic Acid Intense Pulse Light Meibomian Gland Dysfunction Facial Erythema Ocular Rosacea 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Powell FC. Rosacea. N Engl J Med. 2005;352:793–803.CrossRefPubMedGoogle Scholar
  2. 2.
    Bergfeld WF, Fowler JF, Baumann LS, Taylor SC. The four seasons of skin care: the utility of natural ingredients. Cosmet Dermatol. 2004;17(12 S4):1–9.Google Scholar
  3. 3.
    Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne rosacea. J Drugs Dermatol. 2006;5:35–9.PubMedGoogle Scholar
  4. 4.
    Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Nybaek H, Jamec GB. Photodynamic therapy in the treatment of rosacea. Dermatology. 2005;211:135–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57:873–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499–512.CrossRefPubMedGoogle Scholar
  8. 8.
    Auada-Souto MP, Velho PE. Low-strength trichloroacetic acid in the treatment of rosacea. J Eur Acad Dermatol Venereol. 2007;21:1443–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Mc Aleer MA, Powell FC. Complementary and alternative medicine usage in rosacea. Br J Dermatol. 2008;158:1139–41.CrossRefGoogle Scholar
  10. 10.
    Wu J. Treatment of rosacea with herbal ingredients. J Drugs Dermatol. 2006;5:29–32.PubMedGoogle Scholar
  11. 11.
    Wu JJ, Weinstein GD, Kricorian GJ, Kormeili T, McCullough JL. Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. Clin Exp Dermatol. 2007;32:693–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Wilkin J, Dahl M, Detemar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Wolf K. Present and future rosacea treatment. Cutis. 2005;75:4–7.PubMedGoogle Scholar
  14. 14.
    Drott C, Claes G, Olsson-Rex L, Dalman P, Fahlén T, Göthberg G. Successful treatment of facial blushing by endoscopic transthoracic sympathicotomy. Br J Dermatol. 1998;138:639–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Nestor MS, Gold MH, An K, et al. The use of PDT in dermatology: results of a consensus conference. J Drugs Dermatol. 2006;5:140–54.PubMedGoogle Scholar
  16. 16.
    Irvine C, Kumer P, Marks R. Isotretinonin in the treatment of roscaea and rhinophyma. In: Marks R, Plewig G, editors. Acne and related disorders. London: Martin Dunitz; 1998. p. p301–5.Google Scholar
  17. 17.
    el-Azhary RA, Roenigk RK, Wang TD. Spectrum of results after treatment of rhinophyma with the carbon dioxide laser. Mayo Clin Proc. 1991;66:899–905.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.The Charles Center for Dermatology, St. Vincent’s University HospitalUniversity of DublinDublinIreland

Personalised recommendations